{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"99.1","value":"46.59"},{"comment":"Only 1 participant analyzed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"84.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression.\n\nThe following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)","dispersionType":"Full Range","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants with measurements available at time of progression.","reportingStatus":"POSTED","timeFrame":"Time of progression (up to approximately 54 months from pre-treatment screening)","title":"Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression","type":"SECONDARY","unitOfMeasure":"Percent of cells expressing CS1"}